Literature DB >> 7910840

Involvement of CD11b/CD18 in enhanced neutrophil adhesion by Fc gamma receptor stimulation.

T Kusunoki1, S Tsuruta, H Higashi, S Hosoi, D Hata, K Sugie, M Mayumi, H Mikawa.   

Abstract

Neutrophils showed a rapid and transient adhesion to immunoglobulin G (IgG)-coated plates compared with their adhesion to bovine serum albumin (BSA)-coated plates: the adhesion reached a peak after 15 min of incubation and then gradually returned to almost the basal state in 60 min. The addition of monomeric IgG or anti-Fc gamma RII monoclonal antibody (mAb) (IV.3) suppressed the increase in adhesion, whereas anti-Fc gamma RIII mAb (3G8) was hardly effective, indicating that the interaction of Fc gamma R, especially Fc gamma RII, with coated IgG is involved in the process. Adhesion was also blocked by cytochalasin B, suggesting that functional actin filament structures are crucial. Protein kinase inhibitors, erbstatin and genistein, inhibited the adhesion in a dose-dependent manner. The adhesion was inhibited by anti-CD11b (M1/70) and anti-CD18 (MHM23, TS1/18) mAbs. Moreover, neutrophils from a patient with complete leukocyte adhesion deficiency syndrome did not show increased adhesion to IgG-coated plates. The adhesion of neutrophils to fibrinogen- and BSA-coated plates was also increased when Fc gamma R was stimulated in the fluid phase with soluble aggregated IgG, which was also inhibited by anti-CD11b mAb. Stimulation of neutrophil Fc gamma R with soluble aggregated IgG enhanced the expression of CD11b in concert with the enhanced adhesion. These data collectively suggest that stimulation via Fc gamma R evokes a tyrosine kinase-dependent and actin filament-dependent intracellular signal that enhances the specific and nonspecific adhesive activity of neutrophils, presumably through the activation of CD11b/CD18.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910840     DOI: 10.1002/jlb.55.6.735

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Mac-1 promotes FcgammaRIIA-dependent cell spreading and migration on immune complexes.

Authors:  Ying Xiong; Chunzhang Cao; Alexandra Makarova; Brad Hyman; Li Zhang
Journal:  Biochemistry       Date:  2006-07-25       Impact factor: 3.162

2.  Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3.

Authors:  Zhen-Yu Huang; Sharon Hunter; Paul Chien; Moo-Kyung Kim; Tae-Hee Han-Kim; Zena K Indik; Alan D Schreiber
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

3.  CD44-mediated phagocytosis induces inside-out activation of complement receptor-3 in murine macrophages.

Authors:  Eric Vachon; Raiza Martin; Vivian Kwok; Vera Cherepanov; Chung-Wai Chow; Claire M Doerschuk; Jonathan Plumb; Sergio Grinstein; Gregory P Downey
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

4.  A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis.

Authors:  T Tang; A Rosenkranz; K J Assmann; M J Goodman; J C Gutierrez-Ramos; M C Carroll; R S Cotran; T N Mayadas
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

5.  Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia.

Authors:  Jie Ni; Yang Wu; Feng Qi; Xiao Li; Shaorong Yu; Siwen Liu; Jifeng Feng; Yuxiao Zheng
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

6.  The tripeptide feG inhibits leukocyte adhesion.

Authors:  Ronald D Mathison; Emily Christie; Joseph S Davison
Journal:  J Inflamm (Lond)       Date:  2008-05-20       Impact factor: 4.981

7.  Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis.

Authors:  Shuangnian Xu; Xi Li; Jianmin Zhang; Jieping Chen
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.